American Oriental Bioengineering, Inc. Sustainability Profile
American Oriental Bioengineering, Inc., often referred to as AOB, is a prominent player in the biotechnology and pharmaceutical industry, headquartered in China. Founded in 1998, the company has established a strong presence in the development and manufacturing of herbal extracts, dietary supplements, and bio-pharmaceutical products, catering to both domestic and international markets. With a focus on innovative solutions, AOB's core offerings include high-quality herbal extracts and advanced bioengineering products that stand out for their purity and efficacy. The company has achieved significant milestones, including strategic partnerships and expansions that have solidified its market position. Recognised for its commitment to research and development, American Oriental Bioengineering continues to lead in the integration of traditional herbal medicine with modern scientific practices, making it a trusted name in the health and wellness sector.
DitchCarbon Score
How does American Oriental Bioengineering, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
American Oriental Bioengineering, Inc.'s score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
American Oriental Bioengineering, Inc.'s reported carbon emissions
American Oriental Bioengineering, Inc., headquartered in China, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint. As there are no emissions data or reduction initiatives available, it is unclear how American Oriental Bioengineering, Inc. aligns with industry standards for climate action. The absence of specific targets or commitments may reflect a broader trend within the industry, where many companies are increasingly focusing on sustainability and emissions reduction. In summary, without available emissions data or climate commitments, American Oriental Bioengineering, Inc. appears to have limited transparency regarding its carbon emissions and climate strategy.
How Carbon Intensive is American Oriental Bioengineering, Inc.'s Industry?
How Carbon Intensive is American Oriental Bioengineering, Inc.'s Location?
American Oriental Bioengineering, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
American Oriental Bioengineering, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Hunan Er-Kang Pharmaceutical Co., Ltd
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.